<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00434954</url>
  </required_header>
  <id_info>
    <org_study_id>H8O-SB-GWBN</org_study_id>
    <nct_id>NCT00434954</nct_id>
  </id_info>
  <brief_title>Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes</brief_title>
  <official_title>Effect of Exenatide Plus Metformin vs. Premixed Human Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Inadequate Control of Type 2 Diabetes on Oral Antidiabetic Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study in Germany is designed to compare the effects of twice-daily exenatide plus
      metformin and twice-daily premixed human insulin aspart plus metformin with respect to
      glycemic control, as measured by HbA1c, combined with the percentage of patients with at
      least one treatment-emergent hypoglycemic episode. Patients will be treated with study
      therapy for approximately 26 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Glycosylated Hemoglobin (HbA1c)</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Change in HbA1c from baseline after 26 weeks of treatment (i.e., HbA1c at week 26 minus HbA1c at week 0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Hypoglycemia (Percentage of Participants With at Least One Hypoglycemic Episode)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Risk for first hypoglycemic episode (blood glucose &lt;=3.9 mmol/L or severe episode) to occur up to week 26</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving HbA1c Target of &lt; 6.5%</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percentage of subjects achieving HbA1c target of &lt; 6.5% at the end of study (week 26) [i.e., number of subjects who achieved HbA1c &lt; 6.5% divided by total number of subjects times 100%].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving HbA1c Target of &lt; 7.0%</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percentage of subjects achieving HbA1c target of &lt; 7.0% at the end of study (week 26) [i.e., number of subjects who achieved HbA1c &lt; 7.0% divided by total number of subjects times 100%].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hypoglycemic Episodes [Blood Glucose &lt;= 3.0 mmol/L or Severe] (Percentage of Subjects Who Experienced at Least One Treatment-emergent Hypoglycemic Episode During the 26-week Treatment Period)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Risk for the first hypoglycemic episode to occur up to Week 26 (percentage of subjects who experienced at least one treatment-emergent hypoglycemic episode during the 26-week treatment period)[ i.e., number of subjects experiencing at least one hypoglycemic episode divided by total number of subjects times 100%]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Nocturnal Hypoglycemia (Percentage of Subjects Who Experienced at Least One Episode of Nocturnal Hypoglycemia During the 26 Week Treatment Period)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Risk for first nocturnal (night-time) hypoglycemic episode to occur up to week 26 (percentage of subjects who experienced at least one episode of nocturnal hypoglycemia during the 26 week treatment period) [i.e., number of subjects who experienced nocturnal hypoglycemia divided by total number of subjects times 100%].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7 Point Self-monitored Blood Glucose (SMBG) Profiles</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>7-point self-monitored blood glucose profiles at baseline and the end of the study, measured at 7 times during the day (pre-breakfast, 2 hours post-breakfast, pre-lunch, 2 hours post-lunch, pre-dinner, 2 hours post-dinner, and 3:00am).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Lipid Levels</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol (calculated), and triglyceride levels at baseline (week 0) and the end of the study (week 26)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Change in body weight from baseline after 26 weeks of treatment (i.e., body weight at week 26 minus body weight at week 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Mass Index (BMI)</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Change in BMI from baseline after 26 weeks of treatment (i.e., BMI at week 26 minus BMI at week 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes: Diabetes Treatment Satisfaction Questionnaire (DTSQ)</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Total DTSQ treatment satisfaction score at baseline (week 0) and after 26 weeks of treatment (LOCF). Total DTSQ treatment satisfaction score is derived as sum score of the individual components 1 and 4-8 of the DTSQ questionnaire. Each component is scored on a scale of 0 (worst case) to 6 (best case). Higher values represent higher treatment satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes: Quality of Life (SF-12)</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>SF-12 Physical and Mental Component Summary Scores at baseline (week 0) and after 26 weeks of treatment (LOCF). SF-12 Physical and Mental Component Summary Scores are normalized scores ranging from 0 (worst case) to 100 (best case), and are derived from responses to 12 questions. Scores &gt; 50 indicate an above-average health status.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">494</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Exenatide Twice Daily (BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Premixed Insulin Aspart Twice Daily (BID)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exenatide twice daily (BID)</intervention_name>
    <description>subcutaneous injection (5 mcg or 10 mcg), twice a day</description>
    <arm_group_label>Exenatide Twice Daily (BID)</arm_group_label>
    <other_name>Byetta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>premixed insulin aspart twice daily (BID)</intervention_name>
    <description>subcutaneous injection (titrated appropriately), twice a day</description>
    <arm_group_label>Premixed Insulin Aspart Twice Daily (BID)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have been treated with diet and exercise and a stable, maximally tolerated dose of
             immediate-release or extended-release metformin, or the combination of metformin (any
             dosage) with sulfonylurea/meglitinides for at least 3 months prior to study start

          -  Have not received thiazolidinediones, or alpha-glucosidase inhibitors for longer than
             2 weeks within 3 months prior to study start, and have not received any insulin
             formulation for more than 14 days (other than in emergency situations) and within 14
             days prior to study start

          -  Have an HbA1c between 6.5% and 10.0%, inclusive

          -  Have a body mass index (BMI) between 25 kg/m^2 and 40 kg/m^2, inclusive

        Exclusion Criteria:

          -  Have type 1 diabetes or known latent autoimmune diabetes in adults

          -  Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy
             (excluding topical and inhaled preparations) or have received such therapy within 2
             weeks prior to study start

          -  Are receiving treatment for gastrointestinal disease with a drug directly affecting
             gastrointestinal motility (e.g., metoclopramide, cisapride, and chronic macrolide
             antibiotics)

          -  Have used any prescription drug to promote weight loss within 3 months prior to study
             start

          -  Have received treatment within 30 days prior to study start with a drug that has not
             received regulatory approval for any indication at the time of study entry

          -  Have previously completed or withdrawn from this study or any other study
             investigating exenatide or GLP-1 analogs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bad Mergentheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bosenheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burghausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Datteln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Friedrichsthal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hildesheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hirschhorn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hohenmolsen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lehrte</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ludwigsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marktheidenfeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Meissen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Offenbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oschatz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pohlheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riesa</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rodgau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roding</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rosenheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Schluchtern</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Schwedt/Oder</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sinsheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Speyer</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Unterhaching</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Volklingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wallerfing</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wolfsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2007</study_first_submitted>
  <study_first_submitted_qc>February 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2007</study_first_posted>
  <results_first_submitted>June 25, 2010</results_first_submitted>
  <results_first_submitted_qc>July 30, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 23, 2010</results_first_posted>
  <last_update_submitted>March 19, 2015</last_update_submitted>
  <last_update_submitted_qc>March 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>exenatide</keyword>
  <keyword>Byetta</keyword>
  <keyword>Amylin</keyword>
  <keyword>Lilly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Patients treated with metformin (MET only;confirmatory population used for primary analysis) and additional patients treated with metformin plus either sulfonylurea or meglitinide (MET+SU; exploratory population) were enrolled at a 3:1 ratio; metformin was continued.Within each population, patients were then randomly assigned 1:1 to study treatment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Exenatide Twice Daily</title>
          <description>Exenatide 5 mcg twice daily for 4 weeks, followed by 10 mcg twice daily for 26 weeks</description>
        </group>
        <group group_id="P2">
          <title>Premixed Insulin Aspart Twice Daily</title>
          <description>Premixed insulin aspart (70% protamin crystallized, 30% soluble) twice daily, individually titrated to reach target blood glucose levels for 26 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="248"/>
                <participants group_id="P2" count="246"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started - Previous Treatment MET Only</title>
              <participants_list>
                <participants group_id="P1" count="182"/>
                <participants group_id="P2" count="181"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started - Previous Treatment MET + SU</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS) Overall</title>
              <participants_list>
                <participants group_id="P1" count="247">FAS=received &gt;=1 dose of study drug. Adverse event data reported for Overall FAS.</participants>
                <participants group_id="P2" count="233">FAS=received &gt;=1 dose of study drug. Adverse event data reported for Overall FAS.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>FAS - Previous Treatment MET Only</title>
              <participants_list>
                <participants group_id="P1" count="181">Baseline and efficacy data reported for &quot;FAS-Previous Treatment MET Only&quot; group.</participants>
                <participants group_id="P2" count="173">Baseline and efficacy data reported for &quot;FAS-Previous Treatment MET Only&quot; group.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>FAS - Previous Treatment MET + SU</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed - Previous Treatment MET Only</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed - Previous Treatment MET + SU</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry criteria not met</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject decision</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Exenatide Twice Daily</title>
          <description>Exenatide 5 mcg twice daily for 4 weeks, followed by 10 mcg twice daily for 26 weeks</description>
        </group>
        <group group_id="B2">
          <title>Premixed Insulin Aspart Twice Daily</title>
          <description>Premixed insulin aspart (70% protamin crystallized, 30% soluble) twice daily, individually titrated to reach target blood glucose levels for 26 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="181"/>
            <count group_id="B2" value="173"/>
            <count group_id="B3" value="354"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.2" spread="10.03"/>
                    <measurement group_id="B2" value="56.9" spread="9.94"/>
                    <measurement group_id="B3" value="57.1" spread="9.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg / m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.4" spread="4.23"/>
                    <measurement group_id="B2" value="32.9" spread="4.37"/>
                    <measurement group_id="B3" value="33.2" spread="4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99.4" spread="16.22"/>
                    <measurement group_id="B2" value="96.6" spread="17.40"/>
                    <measurement group_id="B3" value="98.0" spread="16.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Diabetes</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.8" spread="4.39"/>
                    <measurement group_id="B2" value="5.2" spread="4.67"/>
                    <measurement group_id="B3" value="5.0" spread="4.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated hemoglobin (HbA1c)</title>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.89" spread="0.822"/>
                    <measurement group_id="B2" value="7.88" spread="0.918"/>
                    <measurement group_id="B3" value="7.88" spread="0.869"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Glycosylated Hemoglobin (HbA1c)</title>
        <description>Change in HbA1c from baseline after 26 weeks of treatment (i.e., HbA1c at week 26 minus HbA1c at week 0)</description>
        <time_frame>Baseline and 26 weeks</time_frame>
        <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS) and had baseline and at least one post-baseline value available</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Twice Daily</title>
            <description>Exenatide 5 mcg twice daily for 4 weeks, followed by 10 mcg twice daily for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>Premixed Insulin Aspart Twice Daily</title>
            <description>Premixed insulin aspart (70% protamin crystallized, 30% soluble) twice daily, individually titrated to reach target blood glucose levels for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycosylated Hemoglobin (HbA1c)</title>
          <description>Change in HbA1c from baseline after 26 weeks of treatment (i.e., HbA1c at week 26 minus HbA1c at week 0)</description>
          <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS) and had baseline and at least one post-baseline value available</population>
          <units>Percentage of glycosylated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="0.05"/>
                    <measurement group_id="O2" value="-1.14" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis was tested hierarchically that 1) exenatide BID is non-inferior to insulin aspart 70/30 BID for glycemic control (change in HbA1c, outcome measure 1), and 2) superior regarding the incidence of hypoglycemia (outcome measure 2). This is the first part of the hierarchical test.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The planned sample size of 366 patients treated with metformin only (assuming 25% dropouts) gave a power of 85% to detect non-inferiority of exenatide BID for change in HbA1c (non-inferiority margin 0.4%; assumed common standard deviation of 1.1%).</non_inferiority_desc>
            <p_value>0.055</p_value>
            <p_value_desc>Non-inferiority: upper limit of 95% Confidence Interval (CI) to be &lt; 0.4%.</p_value_desc>
            <method>Mixed effect model repeat measures(MMRM)</method>
            <method_desc>95% CI of treatment group difference derived from MMRM (treatment, week, baseline HbA1c and interactions as fixed effects); p-value: superiority test</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.003</ci_lower_limit>
            <ci_upper_limit>0.291</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving HbA1c Target of &lt; 6.5%</title>
        <description>Percentage of subjects achieving HbA1c target of &lt; 6.5% at the end of study (week 26) [i.e., number of subjects who achieved HbA1c &lt; 6.5% divided by total number of subjects times 100%].</description>
        <time_frame>26 weeks</time_frame>
        <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS); last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Twice Daily</title>
            <description>Exenatide 5 mcg twice daily for 4 weeks, followed by 10 mcg twice daily for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>Premixed Insulin Aspart Twice Daily</title>
            <description>Premixed insulin aspart (70% protamin crystallized, 30% soluble) twice daily, individually titrated to reach target blood glucose levels for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving HbA1c Target of &lt; 6.5%</title>
          <description>Percentage of subjects achieving HbA1c target of &lt; 6.5% at the end of study (week 26) [i.e., number of subjects who achieved HbA1c &lt; 6.5% divided by total number of subjects times 100%].</description>
          <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS); last observation carried forward</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6"/>
                    <measurement group_id="O2" value="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.554</p_value>
            <method>Chi square test (Pearson)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving HbA1c Target of &lt; 7.0%</title>
        <description>Percentage of subjects achieving HbA1c target of &lt; 7.0% at the end of study (week 26) [i.e., number of subjects who achieved HbA1c &lt; 7.0% divided by total number of subjects times 100%].</description>
        <time_frame>26 weeks</time_frame>
        <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS); last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Twice Daily</title>
            <description>Exenatide 5 mcg twice daily for 4 weeks, followed by 10 mcg twice daily for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>Premixed Insulin Aspart Twice Daily</title>
            <description>Premixed insulin aspart (70% protamin crystallized, 30% soluble) twice daily, individually titrated to reach target blood glucose levels for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving HbA1c Target of &lt; 7.0%</title>
          <description>Percentage of subjects achieving HbA1c target of &lt; 7.0% at the end of study (week 26) [i.e., number of subjects who achieved HbA1c &lt; 7.0% divided by total number of subjects times 100%].</description>
          <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS); last observation carried forward</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2"/>
                    <measurement group_id="O2" value="56.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.159</p_value>
            <method>Chi square test (Pearson)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Hypoglycemic Episodes [Blood Glucose &lt;= 3.0 mmol/L or Severe] (Percentage of Subjects Who Experienced at Least One Treatment-emergent Hypoglycemic Episode During the 26-week Treatment Period)</title>
        <description>Risk for the first hypoglycemic episode to occur up to Week 26 (percentage of subjects who experienced at least one treatment-emergent hypoglycemic episode during the 26-week treatment period)[ i.e., number of subjects experiencing at least one hypoglycemic episode divided by total number of subjects times 100%]</description>
        <time_frame>26 weeks</time_frame>
        <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Twice Daily</title>
            <description>Exenatide 5 mcg twice daily for 4 weeks, followed by 10 mcg twice daily for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>Premixed Insulin Aspart Twice Daily</title>
            <description>Premixed insulin aspart (70% protamin crystallized, 30% soluble) twice daily, individually titrated to reach target blood glucose levels for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hypoglycemic Episodes [Blood Glucose &lt;= 3.0 mmol/L or Severe] (Percentage of Subjects Who Experienced at Least One Treatment-emergent Hypoglycemic Episode During the 26-week Treatment Period)</title>
          <description>Risk for the first hypoglycemic episode to occur up to Week 26 (percentage of subjects who experienced at least one treatment-emergent hypoglycemic episode during the 26-week treatment period)[ i.e., number of subjects experiencing at least one hypoglycemic episode divided by total number of subjects times 100%]</description>
          <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Nocturnal Hypoglycemia (Percentage of Subjects Who Experienced at Least One Episode of Nocturnal Hypoglycemia During the 26 Week Treatment Period)</title>
        <description>Risk for first nocturnal (night-time) hypoglycemic episode to occur up to week 26 (percentage of subjects who experienced at least one episode of nocturnal hypoglycemia during the 26 week treatment period) [i.e., number of subjects who experienced nocturnal hypoglycemia divided by total number of subjects times 100%].</description>
        <time_frame>26 weeks</time_frame>
        <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Twice Daily</title>
            <description>Exenatide 5 mcg twice daily for 4 weeks, followed by 10 mcg twice daily for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>Premixed Insulin Aspart Twice Daily</title>
            <description>Premixed insulin aspart (70% protamin crystallized, 30% soluble) twice daily, individually titrated to reach target blood glucose levels for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Nocturnal Hypoglycemia (Percentage of Subjects Who Experienced at Least One Episode of Nocturnal Hypoglycemia During the 26 Week Treatment Period)</title>
          <description>Risk for first nocturnal (night-time) hypoglycemic episode to occur up to week 26 (percentage of subjects who experienced at least one episode of nocturnal hypoglycemia during the 26 week treatment period) [i.e., number of subjects who experienced nocturnal hypoglycemia divided by total number of subjects times 100%].</description>
          <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                    <measurement group_id="O2" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>7 Point Self-monitored Blood Glucose (SMBG) Profiles</title>
        <description>7-point self-monitored blood glucose profiles at baseline and the end of the study, measured at 7 times during the day (pre-breakfast, 2 hours post-breakfast, pre-lunch, 2 hours post-lunch, pre-dinner, 2 hours post-dinner, and 3:00am).</description>
        <time_frame>Baseline and 26 weeks</time_frame>
        <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS); last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Twice Daily</title>
            <description>Exenatide 5 mcg twice daily for 4 weeks, followed by 10 mcg twice daily for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>Premixed Insulin Aspart Twice Daily</title>
            <description>Premixed insulin aspart (70% protamin crystallized, 30% soluble) twice daily, individually titrated to reach target blood glucose levels for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>7 Point Self-monitored Blood Glucose (SMBG) Profiles</title>
          <description>7-point self-monitored blood glucose profiles at baseline and the end of the study, measured at 7 times during the day (pre-breakfast, 2 hours post-breakfast, pre-lunch, 2 hours post-lunch, pre-dinner, 2 hours post-dinner, and 3:00am).</description>
          <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS); last observation carried forward</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-breakfast at baseline (week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.933" spread="1.7138"/>
                    <measurement group_id="O2" value="9.005" spread="2.0432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-breakfast at endpoint (week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.774" spread="1.7730"/>
                    <measurement group_id="O2" value="7.293" spread="1.3349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hrs post-breakfast at baseline (week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.821" spread="2.5306"/>
                    <measurement group_id="O2" value="10.902" spread="2.8499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hrs post-breakfast at endpoint (week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.014" spread="2.0557"/>
                    <measurement group_id="O2" value="8.304" spread="2.1212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-lunch at baseline (week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.443" spread="2.1814"/>
                    <measurement group_id="O2" value="8.357" spread="2.3221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-lunch at endpoint (week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.506" spread="1.8800"/>
                    <measurement group_id="O2" value="6.656" spread="1.7011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hrs post-lunch at baseline (week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.698" spread="2.2370"/>
                    <measurement group_id="O2" value="9.899" spread="2.6433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hrs post-lunch at endpoint (week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.513" spread="5.8997"/>
                    <measurement group_id="O2" value="8.216" spread="1.6108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dinner at baseline (week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.684" spread="2.0059"/>
                    <measurement group_id="O2" value="8.759" spread="2.2174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dinner at endpoint (week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.616" spread="2.1727"/>
                    <measurement group_id="O2" value="7.194" spread="1.5572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hrs post-dinner at baseline (week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.241" spread="2.2880"/>
                    <measurement group_id="O2" value="10.259" spread="2.4868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hrs post-dinner at endpoint (week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.727" spread="1.8820"/>
                    <measurement group_id="O2" value="8.143" spread="1.5614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3:00 am at baseline (week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.323" spread="1.8692"/>
                    <measurement group_id="O2" value="8.475" spread="2.2643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3:00 am at endpoint (week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.518" spread="1.5861"/>
                    <measurement group_id="O2" value="6.999" spread="1.5596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Lipid Levels</title>
        <description>Total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol (calculated), and triglyceride levels at baseline (week 0) and the end of the study (week 26)</description>
        <time_frame>Baseline and 26 weeks</time_frame>
        <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS); last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Twice Daily</title>
            <description>Exenatide 5 mcg twice daily for 4 weeks, followed by 10 mcg twice daily for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>Premixed Insulin Aspart Twice Daily</title>
            <description>Premixed insulin aspart (70% protamin crystallized, 30% soluble) twice daily, individually titrated to reach target blood glucose levels for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Lipid Levels</title>
          <description>Total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol (calculated), and triglyceride levels at baseline (week 0) and the end of the study (week 26)</description>
          <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS); last observation carried forward</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total cholesterol at baseline (week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.147" spread="1.0008"/>
                    <measurement group_id="O2" value="5.084" spread="1.0079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total cholesterol at endpoint (week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.971" spread="0.9653"/>
                    <measurement group_id="O2" value="5.050" spread="0.8933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL cholesterol at baseline (week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.234" spread="0.3065"/>
                    <measurement group_id="O2" value="1.255" spread="0.3324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL cholesterol at endpoint (week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.244" spread="0.2805"/>
                    <measurement group_id="O2" value="1.319" spread="0.3394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL cholesterol (calculated) at baseline (week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.845" spread="0.8308"/>
                    <measurement group_id="O2" value="2.768" spread="0.8103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL cholesterol (calculated) at endpoint (week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.738" spread="0.8472"/>
                    <measurement group_id="O2" value="2.852" spread="0.8134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides at baseline (week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.391" spread="1.5497"/>
                    <measurement group_id="O2" value="2.410" spread="1.4398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides at endpoint (week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.234" spread="1.1886"/>
                    <measurement group_id="O2" value="2.006" spread="1.2040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Hypoglycemia (Percentage of Participants With at Least One Hypoglycemic Episode)</title>
        <description>Risk for first hypoglycemic episode (blood glucose &lt;=3.9 mmol/L or severe episode) to occur up to week 26</description>
        <time_frame>26 weeks</time_frame>
        <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Twice Daily</title>
            <description>Exenatide 5 mcg twice daily for 4 weeks, followed by 10 mcg twice daily for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>Premixed Insulin Aspart Twice Daily</title>
            <description>Premixed insulin aspart (70% protamin crystallized, 30% soluble) twice daily, individually titrated to reach target blood glucose levels for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hypoglycemia (Percentage of Participants With at Least One Hypoglycemic Episode)</title>
          <description>Risk for first hypoglycemic episode (blood glucose &lt;=3.9 mmol/L or severe episode) to occur up to week 26</description>
          <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis was tested hierarchically that 1) exenatide BID is non-inferior to insulin aspart BID for glycemic control (outcome measure 1), and 2) superior regarding the incidence of hypoglycemia (outcome measure 2).The planned sample size of 366 patients treated with metformin only (assumed dropout rate 25%) gave 96% power to detect superiority of exenatide BID for the risk of hypoglycemia, assuming incidences of 3.6% for exenatide BID and 17.5% for insulin aspart BID (alpha=0.05).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Non overlapping 95% CI's: statistically significant difference p&lt;0.05.</p_value_desc>
            <method>Kaplan-Meier analysis</method>
            <method_desc>For each treatment group, the incidence of hypoglycemia at Week 26 and 95% CIs were derived from Kaplan-Meier analysis.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight</title>
        <description>Change in body weight from baseline after 26 weeks of treatment (i.e., body weight at week 26 minus body weight at week 0)</description>
        <time_frame>Baseline and 26 weeks</time_frame>
        <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS) and had baseline and at least one post-baseline value available; last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Twice Daily</title>
            <description>Exenatide 5 mcg twice daily for 4 weeks, followed by 10 mcg twice daily for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>Premixed Insulin Aspart Twice Daily</title>
            <description>Premixed insulin aspart (70% protamin crystallized, 30% soluble) twice daily, individually titrated to reach target blood glucose levels for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight</title>
          <description>Change in body weight from baseline after 26 weeks of treatment (i.e., body weight at week 26 minus body weight at week 0)</description>
          <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS) and had baseline and at least one post-baseline value available; last observation carried forward</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.10" spread="0.22"/>
                    <measurement group_id="O2" value="1.02" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The MMRM model adjusted for baseline HbA1c stratum (HbA1c at baseline &gt;= 6.5% and &lt;= 8.0% vs. &gt; 8.0% and &lt;=10%).</p_value_desc>
            <method>Mixed effects model repeated measures</method>
            <method_desc>95% CI of treatment group difference derived from MMRM (treatment, week, baseline HbA1c and interactions as fixed effects)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Mass Index (BMI)</title>
        <description>Change in BMI from baseline after 26 weeks of treatment (i.e., BMI at week 26 minus BMI at week 0)</description>
        <time_frame>Baseline and 26 weeks</time_frame>
        <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS) and had baseline and at least one post-baseline value available; last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Twice Daily</title>
            <description>Exenatide 5 mcg twice daily for 4 weeks, followed by 10 mcg twice daily for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>Premixed Insulin Aspart Twice Daily</title>
            <description>Premixed insulin aspart (70% protamin crystallized, 30% soluble) twice daily, individually titrated to reach target blood glucose levels for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Mass Index (BMI)</title>
          <description>Change in BMI from baseline after 26 weeks of treatment (i.e., BMI at week 26 minus BMI at week 0)</description>
          <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS) and had baseline and at least one post-baseline value available; last observation carried forward</population>
          <units>kg/m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.39" spread="0.07"/>
                    <measurement group_id="O2" value="0.32" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The MMRM model adjusted for baseline HbA1c stratum (HbA1c at Visit 1 &gt;= 6.5% and &lt;= 8.0% vs. &gt; 8.0% and &lt;=10%).</p_value_desc>
            <method>Mixed effects model repeated measures</method>
            <method_desc>95% CI of treatment group difference derived from MMRM (treatment, week, baseline HbA1c and interactions as fixed effects)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Reported Outcomes: Diabetes Treatment Satisfaction Questionnaire (DTSQ)</title>
        <description>Total DTSQ treatment satisfaction score at baseline (week 0) and after 26 weeks of treatment (LOCF). Total DTSQ treatment satisfaction score is derived as sum score of the individual components 1 and 4-8 of the DTSQ questionnaire. Each component is scored on a scale of 0 (worst case) to 6 (best case). Higher values represent higher treatment satisfaction.</description>
        <time_frame>Baseline and 26 weeks</time_frame>
        <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS); last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Twice Daily</title>
            <description>Exenatide 5 mcg twice daily for 4 weeks, followed by 10 mcg twice daily for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>Premixed Insulin Aspart Twice Daily</title>
            <description>Premixed insulin aspart (70% protamin crystallized, 30% soluble) twice daily, individually titrated to reach target blood glucose levels for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcomes: Diabetes Treatment Satisfaction Questionnaire (DTSQ)</title>
          <description>Total DTSQ treatment satisfaction score at baseline (week 0) and after 26 weeks of treatment (LOCF). Total DTSQ treatment satisfaction score is derived as sum score of the individual components 1 and 4-8 of the DTSQ questionnaire. Each component is scored on a scale of 0 (worst case) to 6 (best case). Higher values represent higher treatment satisfaction.</description>
          <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS); last observation carried forward</population>
          <units>scores on DTSQ scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DTSQ score at baseline (week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5" spread="6.13"/>
                    <measurement group_id="O2" value="29.7" spread="6.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DTSQ score at endpoint (week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.6" spread="6.05"/>
                    <measurement group_id="O2" value="29.3" spread="6.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Reported Outcomes: Quality of Life (SF-12)</title>
        <description>SF-12 Physical and Mental Component Summary Scores at baseline (week 0) and after 26 weeks of treatment (LOCF). SF-12 Physical and Mental Component Summary Scores are normalized scores ranging from 0 (worst case) to 100 (best case), and are derived from responses to 12 questions. Scores &gt; 50 indicate an above-average health status.</description>
        <time_frame>Baseline and 26 weeks</time_frame>
        <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS); last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Twice Daily</title>
            <description>Exenatide 5 mcg twice daily for 4 weeks, followed by 10 mcg twice daily for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>Premixed Insulin Aspart Twice Daily</title>
            <description>Premixed insulin aspart (70% protamin crystallized, 30% soluble) twice daily, individually titrated to reach target blood glucose levels for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcomes: Quality of Life (SF-12)</title>
          <description>SF-12 Physical and Mental Component Summary Scores at baseline (week 0) and after 26 weeks of treatment (LOCF). SF-12 Physical and Mental Component Summary Scores are normalized scores ranging from 0 (worst case) to 100 (best case), and are derived from responses to 12 questions. Scores &gt; 50 indicate an above-average health status.</description>
          <population>All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS); last observation carried forward</population>
          <units>scores on SF-12 scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Component at baseline (week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5" spread="13.99"/>
                    <measurement group_id="O2" value="36.3" spread="14.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component at endpoint (week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" spread="14.30"/>
                    <measurement group_id="O2" value="37.7" spread="14.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component at baseline (week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3" spread="18.33"/>
                    <measurement group_id="O2" value="28.3" spread="19.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component at endpoint (week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" spread="19.38"/>
                    <measurement group_id="O2" value="29.6" spread="18.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>26 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Exenatide Twice Daily</title>
          <description>Exenatide 5 mcg twice daily for 4 weeks, followed by 10 mcg twice daily for 26 weeks</description>
        </group>
        <group group_id="E2">
          <title>Premixed Insulin Aspart Twice Daily</title>
          <description>Premixed insulin aspart (70% protamin crystallized, 30% soluble) twice daily, individually titrated to reach target blood glucose levels for 26 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter Ohman, Medical Science Director</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

